Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.

When CD19 CAR T-cell therapy fails, CD83 may be the backup plan. Roswell Park researchers found that CAR T cells targeting CD83 can revive the immune attack on B-cell cancers even after CD19 antigen loss renders standard therapy ineffective. Bonus: it may also carry a lower risk of a dangerous side effect called B-cell aplasia.
When the frontline CAR T stops working, CD83 steps up
CAR T-cell therapy targeting CD19 is a game-changer for aggressive B-cell blood cancers — but when the disease relapses after treatment, the outlook turns grim. A key reason: cancer cells can shed the CD19 protein, making the therapy blind to them. Researchers at Roswell Park Comprehensive Cancer Center think they've found a workaround, publishing preclinical findings in the Journal for ImmunoTherapy of Cancer.
Their solution? Redirect CAR T cells to target CD83, a different protein expressed in acute lymphoblastic leukemia (ALL), mantle cell lymphoma (MCL), and diffuse large B-cell lymphoma (DLBCL) — but notably absent in healthy circulating B cells. In both lab and animal models, CD83 CAR T cells successfully attacked cancer cells that had escaped CD19-directed therapy, and also worked effectively as a standalone treatment.
Key Takeaways
Why it matters: For patients who relapse after CD19 CAR T — currently left with very few options — CD83 CAR T could offer a meaningful second chance, with a potentially safer toxicity profile to boot.